Boehringer Ingelheim launches the First Approved Treatment for Idiopathic Pulmonary Fibrosis in Algeria
Nintedanib is the only treatment for Idiopathic Pulmonary Fibrosis approved by the Algerian Ministry of Health
Search
Idiopathic Pulmonary Fibrosis treatment launched in Egypt
Idiopathic Pulmonary Fibrosis treatment launched in Egypt
Boehringer Ingelheim Launches New Arabic Website to Support Patients Living with Idiopathic
Boehringer Ingelheim Launches New Arabic Website to Support Patients Living with Idiopathic Pulmonary Fibrosis in the Region
Pulmonary Fibrosis Awareness Month 2020
Hear what Peter Fang said about pulmonary fibrosis awareness month, our commitment to advancing care and our engaging new campaign, ‘the most important postcard you will ever write’
Pulmonary Fibrosis
Pulmonary Fibrosis
Podcast: Journeys through pulmonary fibrosis
As we speak to the courageous pulmonary fibrosis community, we hear heart-warming stories of determination, resilience and spirit.
Have you heard of Pulmonary Fibrosis?
Pulmonary fibrosis is a devastating condition and can be an isolating disease.Taking charge of your heath starts with awareness and building your knowledge is a powerful way to show you care.
Facts about the INPULSIS™ trials
Professor Richeldi treatment initiation
Leading pulmonologist Professor Richeldi discusses why early initiation of treatment in Idiopathic Pulmonary Fibrosis is important.
IPF treatment discussions
Listen to Steve Jones (a person living wih IPF) and Dr. Marlies Wijsenbeek (a leading pulmonologist) discuss the importance of treatment discussions in IPF
What are acute exacerbations in IPF?
Risk factors for acute exacerbations in IPF are unclear, but there is evidence that a number of factors may increase risk. Learn more here.
L'Arte di Respirare IN IPF
Expert Prof. Richeldi discusses the link between Idiopathic Pulmonary Fibrosis (IPF) and Leonardo da Vinci and importance of taking action early.
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Boehringer Ingelheim Teams Up with the Lebanese Pulmonary Society (LPS) in its Fight against COVID-19
Boehringer Ingelheim Teams Up with the Lebanese Pulmonary Society (LPS) in its Fight against COVID-19
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52 versus placebo.
Boehringer launches the Treatment for Three Interstitial Lung Diseases in Qatar
• This is the first time that an approved antifibrotic medication will be available for ILD patients residing in Qatar
IPF Video Infographic
Boehringer Ingelheim Builds on 100 Years of Expertise To Continue Raising Awareness of Respiratory
Boehringer Ingelheim Builds on 100 Years of Expertise To Continue Raising Awareness of Respiratory Diseases
Ofev®
Ofev® is a prescription medication used to treat people with idiopathic pulmonary fibrosis (IPF) systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic fibrosing interstitial lung diseases with a progressive phenotype
Our Partners Harvard
Brock Reeve, Executive Director of the Harvard Stem Cell Institute, talks about the importance of working together to tackle the challenge of fibrosis.
Boehringer Ingelheim Saudi Arabia Hosts Virtual Summit on the Latest Updates in Diabetes, Cardio
Boehringer Ingelheim Saudi Arabia Hosts Virtual Summit on the Latest Updates in Diabetes, Cardio-Metabolism, Respiratory Diseases and Stroke Management
Lung Diseases
Lung Diseases
Lung Repair & Regeneration Video
Lung repair & regeneration research addresses fundamental changes to lung architecture and how these changes impact lung function.
Facts About IPF
IPF is a debilitating and fatal lung disease.
More than 140 healthcare professionals gather at 3rd edition of Interstitial Lung Disease Summit to discuss latest scientific guidelines
The ILD summit discussed the latest treatment guidelines for ILD which vastly impacts quality of life